VenaSeal is an FDA-approved, minimally invasive treatment for varicose veins. It is the first of its kind that uses a cyanoacrylate adhesive (a medical-grade “glue”) to permanently seal the diseased vein. A catheter is inserted into the diseased vein. Ultrasound is used to guide the injection of small amounts of the adhesive into the vein. Once the “glue” is placed, the catheter is removed. The treated vein is permanently closed and blood flow will reroute to nearby veins. Eventually, the body will reabsorb the treated vein and it will disappear completely.
Because the insertion site is so small, there is no need for anesthesia or stitches. There are few, if any, side effects and most patients immediately return to their normal activities with no pain, scarring, downtime or recovery time.
VNUS Closure is the gold standard of care for venous insufficiency. It is FDA-approved and has been perfected over the last 20 years, giving patients a minimally invasive, highly effective treatment for their varicose veins. Most patients experience little or no bruising, swelling or pain after the procedure and begin to see resolution of their varicose vein symptoms in one to two weeks following their VNUS Closure procedure.
To begin the VNUS Closure procedure, local anesthesia is administered to numb the treatment area and make the patient comfortable. Ultrasound helps guide the catheter into the base of the diseased vein and then the catheter is threaded upward to the top of the vein. As the catheter is slowly removed, radiofrequency energy is emitted into the vein. The radiofrequency energy heats the vein wall, causing the vein to contract, collapse and close. Blood flow will be directed to other veins. Eventually, the body will absorb and permanently remove the treated vein. After the procedure, patients can drive themselves to work or home. Walking is encouraged; however, heaving lifting and exertion should be avoided for three days.
ClariVein is a dual-action, chemical-mechanical treatment for small varicose veins. The spinning, mechanical tip of the catheter causes trauma to the vein wall while the chemical sclerosant medication adds further injury to the lining of the vein. Together, the mechanical and chemical components of the treatment cause the vein to collapse, seal off and die. The body will absorb the vein and blood will continue to move through neighboring veins.
A small amount of local anesthesia is administered at the insertion site to make the patient comfortable. Ultrasound is used to visualize the diseased vein so that the ClariVein device can be inserted into the correct location. The ClariVein device has a small needle on the end of it that is inserted into the skin to gain access to the vein. Once the needle is in the vein, a thin, flexible catheter is threaded through the length of the vein. As the catheter is slowly removed, the angled tip spins while it simultaneously administers a sclerosant along the entire vein. This may feel like a mild vibration but should not be painful. Most patients return to work and their normal activities immediately following their ClariVein procedure.
Varithena is the only foam sclerosant approved by the FDA to treat diseased veins within the great saphenous vein system. Varithena can be utilized above and below the knee and can treat varicose veins of all sizes and complexities. The microfoam state of Varithena makes it different from other liquid sclerosants. The microfoam wholly and thoroughly coats the lining of the vein, which improves the effectiveness of the treatment.
The Varithena procedure is minimally invasive and easily tolerated. A small amount of anesthesia is administered at the injection site. Then a catheter is inserted into the diseased vein and Varithena microfoam is injected into the vein. The foaming action completely coats the vein wall, causing irritation and injury to the vein, resulting in the collapse and closure of the diseased vein. Blood will reroute to nearby healthy veins. After the procedure, patients can resume work and normal activities the day of treatment; however, a compression stocking must be worn for three days following treatment.